Country: Canada
Language: English
Source: Health Canada
CANDESARTAN CILEXETIL
APOTEX INC
C09CA06
CANDESARTAN
8MG
TABLET
CANDESARTAN CILEXETIL 8MG
ORAL
100/500
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0135220002; AHFS:
APPROVED
2011-04-26
_APO-CANDESARTAN Tablets Product Monograph_ Page 1 of 34 PRODUCT MONOGRAPH PR APO-CANDESARTAN CANDESARTAN CILEXETIL TABLETS USP 4 MG, 8 MG, 16 MG AND 32 MG ANGIOTENSIN II AT 1 RECEPTOR BLOCKER APOTEX INC. DATE OF REVISION: 150 SIGNET DRIVE JANUARY 29, 2019 TORONTO, ONTARIO M9L 1T9 CONTROL NUMBER: 222632 _APO-CANDESARTAN Tablets Product Monograph_ Page 2 of 34 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 3 _SUMMARY PRODUCT INFORMATION ................................................................................................. 3_ _INDICATIONS AND CLINICAL USE ....................................................................................................... 3_ _CONTRAINDICATIONS ........................................................................................................................... 3_ _WARNINGS AND PRECAUTIONS.......................................................................................................... 4_ _ADVERSE REACTIONS .......................................................................................................................... 7_ _DRUG INTERACTIONS ......................................................................................................................... 13_ _DOSAGE AND ADMINISTRATION ....................................................................................................... 16_ _OVERDOSAGE ..................................................................................................................................... 18_ _ACTION AND CLINICAL PHARMACOLOGY ........................................................................................ 18_ _STORAGE AND STABILITY .................................................................................................................. 21_ _DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................................... 21_ PART II: SCIENTIFIC INFORMATION .................. Read the complete document